Anti-C1q in systemic lupus erythematosus

Stojan, George; Petri, Michelle

doi:10.1177/0961203316645205

Cited by 50 publications

(38 citation statements)

References 50 publications

(84 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the single-variate analyses, anti-C1q antibodies using the standard cut-off value showed the highest OR both for active disease and for LN when using the cut-off proposed in the direction insert of the assays. This is in line with previous studies showing high clinical value in the monitoring of LN patients [ 3 – 7 , 11 , 24 – 26 ]. However, when considering the titer of the antibodies, anti-dsDNA antibodies when present at high titers showed very high OR for LN (at 390 CU, OR = 16).…”

Section: Discussionsupporting

confidence: 92%

“…This study verifies the correlation of anti-dsDNA [ 1 ] and anti-C1q autoantibodies, [ 7 , 22 ] with DA in SLE and LN. In addition, the data demonstrate the utility of a two-parametric model approach using biomarkers for assessing SLE patients for more active and severe disease, especially for patients that have, had a history of, or may develop LN.…”

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus

Sjöwall

Bentow

Aure

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

Objective Anti-double-stranded (ds) DNA and anti-C1q autoantibodies are useful tools in the assessment of disease activity and nephritis in systemic lupus erythematosus (SLE) patients. This study aimed to explore the utility of these antibodies along with anti-Ku antibodies in an oligoparametric model approach for the assessment of disease activity and lupus nephritis. Methods Samples from 261 well-characterized SLE patients were tested using chemiluminescent immunoassays (CIA) for anti-dsDNA and anti-Ku antibodies as well as by anti-C1q antibody ELISA (Inova Diagnostics, USA). Of these SLE patients, 26.4% had lupus nephritis (LN) at the time of blood draw or had a history of LN, and modified SLE disease activity index-2K (SLEDAI) scores were used to assess disease activity. Results All three antibodies demonstrated higher prevalence and higher antibody levels in active versus inactive SLE patients and in LN versus non-LN patients. When oligoparametric analysis was performed, the likelihood of LN and patients with active disease increased with dual and triple positivity. Conclusions Anti-dsDNA and anti-C1q antibodies are useful tools to identify disease activity and/or renal involvement in SLE patients. In addition, the combination of those antibodies in a two-parametric score might improve the clinical utility of those markers.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 79%

Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus

Sjöwall

Bentow

Aure

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Recently, it has been demonstrated that any de ciency in complement activation through classic and alternative pathways strongly correlated with the progression and severity of LN. Among these complement components, C1q and C3b are the most widely explored factors and have a crucial role in facilitating the clearance of immune complexes and cell residue [9,28]. In this regard, the production of antibodies against C1q may result in the formation of circulating or local complexes of C1q and anti-C1q antibodies.…”

Section: Discussionmentioning

confidence: 99%

The Concurrent Anti-C1q and Anti-dsDNA but not Anti-C3b Antibodies as Potent Biomarkers for Lupus Nephritis prediction

Kianmehr¹,

Khoshmirsafa²,

Shekarabi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Lupus Nephritis (LN) in patients with Systemic Lupus Erythematosus (SLE) is one of the most serious and prevalent manifestations. The procedure of renal biopsy is harmful and accompanied by potential hazards. Therefore, introducing reliable biomarkers to predict LN is exceedingly worthwhile. In the current study, we compared the diagnostic values of circulating autoantibodies against dsDNA, C1q, C3b, SSA, SSB, and Sm alone or in combination to predict LN.Methods: This study evaluated abovementioned autoantibodies in 40 healthy controls (HCs) and 95 SLE patients with different kidney involvements, including absent (n = 40), inactive (n = 20), and active (n= 35) LN using EIA method.Result: The frequency and odds ratio of anti-dsDNA (71.4%, OR=4.2), anti-C1q (62.9%, OR= 5.1), and the simultaneous existence of anti-C1q and anti-dsDNA (51.4%, OR=6) antibodies were significantly higher in the active LN group compared with both inactive and absent LN groups. Moreover, the levels of anti-C1q and anti-dsDNA antibodies positively correlated with disease activity in patients with SLE. The prevalence of these autoantibodies was associated with the severity of LN biopsies. Conclusion: These data suggest that anti-C1q and anti-dsDNA antibodies and also the simultaneous presence of them may be valuable diagnostic biomarkers for LN prediction in patients with SLE.

show abstract

“…Increased C1q production in patients with active pulmonary tuberculosis (TB) compared to latent TB has recently been reported indicating the potential use of C1q as biomarker to discriminate between patients with active TB cases from latent TB [ 16 ]. C1q has also been implicated in several immune-complex disorders such as acute glomerulonephritis [ 18 ] and acute systemic lupus erythematosus (SLE) [ 19 , 20 ] and rheumatoid arthritis [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Complement C1q expression in Erythema nodosum leprosum

et al. 2018

View full text Add to dashboard Cite

Complement C1q is a soluble protein capable of initiating components of the classical pathway in host defence system. In earlier qualitative studies, C1q has been implicated in the pathogenesis of Erythema Nodosum Leprosum (ENL). However, little is known about the role of this complement in ENL reaction. In the present study we described the protein level of C1q production and its gene expression in the peripheral blood and skin biopsies in patients with ENL reaction and lepromatous leprosy (LL) patient controls before and after treatment. Thirty untreated patients with ENL reaction and 30 non-reactional LL patient controls were recruited at ALERT Hospital, Ethiopia. Peripheral blood and skin biopsies were obtained from each patient before and after treatment. The level of circulating C1q in the plasma was determined by enzyme-linked immunosorbent assay. The mRNA expression of the three C1q components, C1qA, C1qB, and C1qC in the peripheral blood and skin biopsies was determined by qPCR. Circulating C1q in the peripheral blood of untreated ENL patients was significantly decreased compared to LL patient controls. Untreated ENL patients had increased C1q gene expression in the peripheral blood compared to LL controls. Similarly, C1qA and C1qC gene expression were substantially increased in the skin biopsies of untreated ENL patients compared to LL controls. However, after treatment none of these genes show significant difference in both groups. In conclusion, while circulating C1q is inversely correlated with active ENL reactions, its gene expression is directly correlated with ENL. The decreased circulating C1q may suggest the utilization of C1q in immune-complex formation in these patients. Therefore, C1q could be a potential diagnostic marker for active ENL reactions as well as for monitoring ENL treatment.

show abstract

Anti-C1q in systemic lupus erythematosus

Cited by 50 publications

References 50 publications

Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus

Two-Parametric Immunological Score Development for Assessing Renal Involvement and Disease Activity in Systemic Lupus Erythematosus

The Concurrent Anti-C1q and Anti-dsDNA but not Anti-C3b Antibodies as Potent Biomarkers for Lupus Nephritis prediction

Complement C1q expression in Erythema nodosum leprosum

Contact Info

Product

Resources

About